- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
MAP2K2 Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP7961a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
MAP2K2 Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | P36507 |
| Clone Names | 3032111 |
| Calculated MW | 44424 Da |
MAP2K2 Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 5605 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP7961a was selected from the N-term region of human MAP2K2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
MAP2K2 Antibody (N-term) Blocking Peptide - Protein Information | |
| Name MAP2K2 | |
| Synonyms MEK2, MKK2, PRKMK2 | |
| Function Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity) | |
MAP2K2 Antibody (N-term) Blocking Peptide - Related products
AP3452a: Phospho-MAP2K2-S226 Antibody
AP3489a: Phospho-MAP2K2-T394 Antibody
AP7905a: MEK2 Antibody (N-term)
AP7961a: MEK2 (MAP2K2) Antibody (N-term)
AP7961c: MEK2 (MAP2K2) Antibody (Center)
AP7961d: MAP2K2 Antibody (T394)
AP7961e: MAP2K2 Antibody (S222)
AP7961f: MAP2K2 Antibody (S226)
RI13155: MAP2K2 predesign siRNA
LY10316a: MAP2K2 Over-expression Lysate
BP3452a: Phospho-MAP2K2-S226 Antibody Blocking Peptide
BP3489a: Phospho-MAP2K2-T394 Antibody Blocking Peptide
BP7905a: MEK2 Antibody (N-term) Blocking Peptide
BP7961a: MAP2K2 Antibody (N-term) Blocking Peptide
BP7961c: MAP2K2 Antibody (Center) Blocking Peptide
BP7961d: MAP2K2 Antibody (T394) Blocking Peptide
BP7961e: MAP2K2 Antibody (S222) Blocking Peptide
MAP2K2 Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
MAP2K2 is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. The inhibition or degradation of this kinase is found to be involved in the pathogenesis of Yersinia and anthrax.
REFERENCES
Burroughs, K.D., et al., Mol. Cancer Res. 1(4):312-322 (2003).Tran, H., et al., Mol. Cell. Biol. 23(20):7177-7188 (2003).Li, S.P., et al., Cancer Res. 63(13):3473-3477 (2003).Li, Y., et al., J. Biol. Chem. 278(16):13663-13671 (2003).Liu, X., et al., J. Biol. Chem. 277(42):39312-39319 (2002).
